Common Misconceptions About Neuroinflammation

What neuroinflammation actually is

Neuroinflammation is the umbrella term for the immune and inflammatory responses mounted within the central nervous system. It is not a synonym for microglial activation, and it is not a single pathway. The term covers cytokine release, glial reactivity, inflammasome assembly, leukocyte infiltration, and metabolic shifts in neurons and astrocytes. The evidence base for this page centres on the NLRP3 inflammasome and the AMPK–mTOR signalling axis, with additional material on NMDA receptor blockade, NAD⁺ homeostasis, and bile-acid signalling.

Two misconceptions recur. The first is that neuroinflammation is always harmful. The second is that any compound described as anti-inflammatory in a rodent model will behave the same way in humans. Neither is supported by the literature summarised here. Several of the studies below are animal-only or in vitro, and are labelled as such.

Research Studies

AMPK activators and NLRP3 inflammasome-mediated neuroinflammation in a rat weight-drop TBI model

Traumatic brain injury disrupts AMPK signalling, impairs energy homeostasis, and activates inflammatory pathways. In a weight-drop model of traumatic brain injury in Sprague-Dawley rats, AMPK activation was associated with suppression of NLRP3 inflammasome-mediated neuroinflammation. The AMPK activators examined included metformin, quercetin, resveratrol, cinnamaldehyde, and berberine [3]. This is an animal model; the findings do not establish human efficacy.

Magnesium sulphate and NMDA receptor blockade in term neonates with birth asphyxia

Neonatal asphyxia frequently results in hypoxic-ischaemic encephalopathy. Intravenous magnesium sulphate blocks NMDA receptors, limiting cellular calcium influx and neuroinflammation. A randomised controlled trial is evaluating adjuvant intravenous magnesium sulphate at 250 mg/kg within 6 hours of birth, with duration of hospital stay and short-term clinical outcomes as endpoints, in term neonates with birth asphyxia in settings where therapeutic hypothermia is unavailable [1]. This is a trial protocol; results are not yet reported here.

Tauroursodeoxycholate and liver-targeted therapy in diabetic macular edema

Diabetic macular edema is a later-stage complication of diabetic retinopathy. Conventional therapies target local vascular dysfunction and provide transient visual improvement. Evidence suggests hepatic metabolic dysfunction is linked to the neuroinflammation and vascular dysfunction seen in diabetic retinopathy. A trial is investigating nutraceutical approaches including tauroursodeoxycholate, a bile acid, and modified traditional Chinese medicine formulations [2]. This is a trial record; no efficacy conclusion is drawn here.

Oxiracetam and cognitive dysfunction across neurological disorders

A narrative review evaluated the mechanistic basis, clinical efficacy, and safety profile of oxiracetam across cognitive impairment associated with ageing, neurodegenerative disease, stroke, and traumatic brain injury. Existing pharmacological treatments, including cholinesterase inhibitors and memantine, were described as providing limited and variable benefit. The review synthesised preclinical and clinical literature, including pharmacodynamic studies of cholinergic effects [6].

NMNAT-1 and NAD⁺ homeostasis in neuroprotection and ageing

NAD⁺ supports redox reactions, DNA repair, chromatin regulation, stress adaptation, inflammation, and neuronal maintenance. Age-associated NAD⁺ decline has been implicated in brain ageing and neurodegenerative disorders, but the causal node and limiting compartment differ across tissues and disease states. NMNAT-1 catalyses the final step in NAD⁺ biosynthesis and is the major nuclear isoform of the mammalian NMNAT family. Direct human genetic evidence establishes NMNAT-1 as a causal gene in inherited axonopathy [7].

Coenzyme Q10 and sevoflurane-induced neuroinflammation in mouse hippocampal neurons

A study reported that coenzyme Q10 alleviated sevoflurane-induced neuroinflammation by regulating apolipoprotein E and phosphorylated tau in mouse hippocampal neurons. A corrigendum subsequently stated that the authors had used an antibody against PHD finger protein 1 (cat. no. ab184951) intending to detect tau phosphorylation at Ser396/404, and acknowledged this as a methodological error affecting the western blot results [8]. The original finding should be read alongside this correction. This was a mouse study.

Natural medicines for Alzheimer's disease: bibliometric mapping and mechanistic synthesis

A bibliometric analysis and narrative review mapped publications in the Web of Science Core Collection from 1 January 2001 to 28 April 2025 using VOSviewer and CiteSpace, then examined representative mechanistic evidence through focused narrative synthesis [4]. The review characterises research trends rather than establishing clinical efficacy for any single natural medicine.

Protein-energy wasting and anabolic resistance in advanced chronic kidney disease

Protein-energy wasting drives morbidity and mortality in advanced chronic kidney disease. A proposed framework describes a nutritional paradox in which a subset of uraemic patients shows systemic anabolic resistance, rendering standard nutritional interventions including oral supplements and intradialytic parenteral nutrition often insufficient [5]. This is a conceptual model, not a trial of a neuroinflammation-targeted compound.

Comparison of model systems and evidence strength

Reference-only findings

Several papers support this page without forming its core. A system-level model of Parkinson's disease reframes the disorder as a multicellular failure of the neuroglial unit, positioning astrocyte dysfunction as an active driver of pathogenesis [9]. In bilirubin encephalopathy, unconjugated bilirubin-induced neuroinflammation is reported to play a pivotal role, with microglial lipophagy modulated via AMPK–mTOR signalling [10]. Pterostilbene has been examined in hyperhomocysteinaemia-induced cognitive impairment using in silico, proteomic, and experimental validation approaches [11]. In ischaemic cerebral injury, TRIM28 was found to SUMOylate IRF3 in astrocytes, driving neutrophil infiltration [12]. These are mechanistic findings from the cited models and do not establish human therapeutic effects.

If you are reading this for personal health reasons

The materials described here are sold for laboratory research only, and we do not provide dosing or medical guidance. Nothing on this page is a recommendation for human use. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] Magnesium Sulphate for Neonatal Asphyxia and Length of Hospital Stay
• [2] Integrative Liver-Targeted Therapy for Diabetic Macular Edema
• [3] AMPK activation and NLRP3 inflammasome-mediated neuroinflammation in a weight-drop TBI model
• [4] Research Trends and Mechanistic Insights Into Natural Medicines for Alzheimer's Disease
• [5] Perspectives on the Nutritional Paradox in Uremia
• [6] Therapeutic Potential of Oxiracetam in Neurocognitive Disorders
• [7] NMNAT-1 and NAD⁺ Homeostasis in Neuroprotection and Aging
• [8] Corrigendum: Coenzyme Q10 alleviates sevoflurane-induced neuroinflammation
• [9] Convergent Astrocytic Failure in Parkinson's Disease
• [10] Bilirubin impacts microglial lipophagy via the AMPK-mTOR signaling pathway
• [11] Triangulating the Neuroprotective Mechanisms of Pterostilbene in Hyperhomocysteinemia Induced Cognitive Impairment
• [12] TRIM28 SUMOylates IRF3 in astrocytes to drive neutrophils infiltration and ischemic cerebral injury